Image is for illustration only. Actual medication labels identify the licensed compounding pharmacy that dispenses your prescription; DirectRxCare is not a pharmacy and does not compound medications.
- Dual-action GLP-1 and GIP receptor agonist
- Up to 22% body weight reduction in trials
- Superior appetite suppression
- Improves insulin sensitivity
- Once-weekly self-injection
- Customized dosing plan
Tirzepatide
Dual-action help with appetite control & weight loss
Important Information
- Already taking this medication? If you are not new to this treatment and need to continue at your current dose or move to a higher dose, you will need to provide supporting documentation (such as a recent prescription, pharmacy label, or provider records) showing you have recently been on it. Without this, your provider will start you at the beginning dose.
Compounded Tirzepatide is a dual GLP-1/GIP receptor agonist offering the most powerful weight loss results available through telehealth.
Choose Your Plan
100% Money-Back Guarantee if Not Approved. Cancel anytime.
Please note: your medication will arrive in a bottle or vial with the dispensing pharmacy's branding and labeling — packaging may differ from the product image shown.
The Why
Why Tirzepatide?
"Because you deserve the most powerful tool science has to offer. Tirzepatide doesn't just suppress appetite — it rewires your metabolism through dual-action pathways. If you're serious about transformation, this is the gold standard."
"I tried everything — keto, intermittent fasting, gym 5x a week. Tirzepatide was the missing piece. Down 42 lbs in 4 months. My doctor says my bloodwork has never looked better."
Michael R.
Verified Patient
The Science Behind Tirzepatide
The first dual GIP + GLP-1 receptor agonist
up to ~21%
Avg. weight reduction at highest dose (SURMOUNT-1)
2
Hormone pathways targeted
72 wks
Length of the pivotal trial
How It Works
Tirzepatide activates two natural gut-hormone receptors — GIP and GLP-1. Together they reduce appetite, increase feelings of fullness, and improve how the body handles sugar and fat.
Key Facts
- The active ingredient was FDA-approved for type 2 diabetes in 2022 and for chronic weight management in 2023.
- In the SURMOUNT-5 head-to-head study (2025), tirzepatide produced greater average weight reduction than semaglutide.
- Dosing starts low and increases every few weeks to improve tolerability.
- Common side effects are digestive (nausea, diarrhea, constipation) and usually ease as the body adjusts.
Published Research
SURMOUNT-1 Trial
New England Journal of Medicine, 2022
In 2,539 adults with obesity, once-weekly tirzepatide produced average weight reductions of roughly 15% to 21% (depending on dose) over 72 weeks, versus about 3% with placebo.
SURMOUNT-4 Trial
JAMA, 2024
Participants who continued tirzepatide maintained and extended their weight reduction, while those switched to placebo regained a substantial portion — highlighting the value of ongoing, supervised treatment.
Research summaries describe published studies of the active ingredient and are provided for education only. Compounded medications are not FDA-approved and were not the products studied. Individual results vary; a licensed provider will determine whether treatment is appropriate for you.
FAQ
